Cargando…

Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab

Nivolumab and ipilimumab (NIVO + IPI) is standard therapy for patients with advanced renal cell carcinoma (RCC). Absolute lymphocyte count (ALC) is a valuable prognostic factor in patients with various cancers treated with immune checkpoint inhibitors. Herein, we determined the prognostic value of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueda, Kosuke, Ogasawara, Naoyuki, Ito, Naoki, Ohnishi, Satoshi, Suekane, Hiroki, Kurose, Hirofumi, Hiroshige, Tasuku, Chikui, Katsuaki, Uemura, Keiichiro, Nishihara, Kiyoaki, Nakiri, Makoto, Suekane, Shigetaka, Igawa, Tsukasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053370/ https://www.ncbi.nlm.nih.gov/pubmed/36983417 http://dx.doi.org/10.3390/jcm12062417

Ejemplares similares

Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report
por: Ueda, Kosuke, et al.
Publicado: (2016)

A Laparoscopic Management Combined with a Flexible Ureteroscope for Ureteral Polyps of More Than 3 cm Length
por: Matsuo, Mitsunori, et al.
Publicado: (2016)

Impact of Gleason score of the tumor at the positive surgical margin as a prognostic factor
por: Kurose, Hirofumi, et al.
Publicado: (2022)

Paraganglioma of the urinary bladder: Case report and literature review
por: Kurose, Hirofumi, et al.
Publicado: (2020)

Synchronous primary triple urogenital malignant tumors of kidney, prostate and bladder
por: Kurose, Hirofumi, et al.
Publicado: (2020)

Clinical outcomes of iodine-125 low-dose-rate brachytherapy for localized prostate cancer: a single-institution review in Japan
por: Nakiri, Makoto, et al.
Publicado: (2022)

Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate
por: Nakiri, Makoto, et al.
Publicado: (2022)

A useful treatment for patients with advanced mixed-type small cell neuroendocrine carcinoma of the prostate: A case report
por: UEMURA, KEI-ICHIRO, et al.
Publicado: (2013)

Seed lost to perineum from hydrogel spacer after brachytherapy for prostate cancer
por: Nakiri, Makoto, et al.
Publicado: (2023)

Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)

Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma
por: Matsuo, Yuko, et al.
Publicado: (2023)

Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer
por: Hiroshige, Tasuku, et al.
Publicado: (2018)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Analysis of radioactive implant migration in patients treated with iodine-125 seeds for permanent prostate brachytherapy with MRI-classified median lobe hyperplasia
por: Muraki, Koichiro, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Remarkable antitumor effect of nivolumab in a patient with metastatic renal cell carcinoma previously treated with a peptide‐based vaccine
por: Kurahashi, Ryoma, et al.
Publicado: (2020)

Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
por: Watanabe, Hirofumi, et al.
Publicado: (2020)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
por: Noguchi, Masanori, et al.
Publicado: (2013)

Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
por: Fuchizawa, Hirotaka, et al.
Publicado: (2021)

Aldehyde Dehydrogenase 1 Identifies Cells with Cancer Stem Cell-Like Properties in a Human Renal Cell Carcinoma Cell Line
por: Ueda, Kosuke, et al.
Publicado: (2013)

Histocompatibility Leukocyte Antigen‐A2‐restricted and Tumor‐specific Cytotoxic T Lymphocytes from Tumor‐infiltrating Lymphocytes of a Patient with Testicular Embryonal Cancer
por: Suekane, Shigetaka, et al.
Publicado: (1997)

Immune responses of patients without cancer recurrence after a cancer vaccine over a long term
por: Suekane, Shigetaka, et al.
Publicado: (2022)

Three-dimensional analysis of interstitial cells in the lamina propria of the murine vas deferens by confocal laser scanning microscopy and FIB/SEM
por: Hiroshige, Tasuku, et al.
Publicado: (2022)

Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
por: Motonaga, Aoi, et al.
Publicado: (2021)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Ipilimumab/nivolumab/tozinameran: Various toxicities: case report
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Identification of PDGFRα-positive interstitial cells in the distal segment of the murine vas deferens
por: Hiroshige, Tasuku, et al.
Publicado: (2021)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
por: Suozzi, Kathleen C., et al.
Publicado: (2016)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b0g56m3kheu311e5he7g28v5n2